Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Amicus Therapeutics is a biotechnology business based in the US. Amicus Therapeutics shares (FOLD) are listed on the NASDAQ and all prices are listed in US Dollars. Amicus Therapeutics employs 496 staff and has a trailing 12-month revenue of around $323.3 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $12.68 |
|---|---|
| 52-week range | $5.91 - $13.62 |
| 50-day moving average | $12.14 |
| 200-day moving average | $10.52 |
| Wall St. target price | $15.40 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.97 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.68 from 2023-02-07
| 1 week (2023-02-01) | -3.65% |
|---|---|
| 1 month (2023-01-06) | 7.64% |
| 3 months (2022-11-08) | 17.73% |
| 6 months (2022-08-08) | 1.12% |
| 1 year (2022-02-04) | N/A |
|---|---|
| 2 years (2021-02-08) | -36.15% |
| 3 years (2020-02-07) | 23.59% |
| 5 years (2018-02-08) | 14.875 |
| Revenue TTM | $323.3 million |
|---|---|
| Gross profit TTM | $271 million |
| Return on assets TTM | -17.05% |
| Return on equity TTM | -103.69% |
| Profit margin | -81.65% |
| Book value | $0.47 |
| Market capitalisation | $3.7 billion |
TTM: trailing 12 months
We're not expecting Amicus Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Amicus Therapeutics's shares have ranged in value from as little as $5.91 up to $13.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amicus Therapeutics's is 0.8518. This would suggest that Amicus Therapeutics's shares are less volatile than average (for this exchange).
Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.